Relative increases in the antiarrhythmic-induced gA channel appearance frequencies and lifetimes
| gA single-channel properties | Amiodarone | Dronedarone | Propranolol | Pindolol | |||||||
| 3 µM | 10 µM | 0.3 µM | 1 µM | 3 µM | 100 µM | 300 µM | 1,000 µM | 100 µM | 300 µM | 1,000 µM | |
| f13/f13cntrl | 2.5 ± 0.7 | 6.5 ± 0.3 | 2.1 ± 0.1 | 4.2 ± 1.2 | 1.6 ± 0.4 | 4.4 ± 0.3 | 9 | 3 ± 1 | 4.0 ± 1.2 | 5 | |
| f15/f15cntrl | 3.1 ± 0.5 | 3.6 ± 1.2 | 1.7 ± 0.03 | 2.2 ± 0.7 | 1.8 ± 0.6 | 6.5 ± 0.2 | 11 | 2.2 ± 0.4 | 3.4 ± 1.1 | 4 | |
| τ13/τ13cntrl | 1.6 ± 0.2 | 3.5 ± 0.2 | 1.5 ± 0.1 | 2.2 ± 0.2 | 4.6 ± 0.8 | 1.1 ± 0.1 | 1.2 ± 0.03 | 1.8 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.4 ± 0.3 |
| τ15/τ15cntrl | 1.5 ± 0.3 | 2.3 ± 0.04 | 1.2 ± 0.1 | 1.6 ± 0.3 | 3.0 ± 0.8 | 1.0 ± 0.05 | 1.1 ± 0.1 | 1.4 ± 0.02 | 1.1 ± 0.1 | 1.2 ± 0.2 | 1.3 ± 0.1 |
| gA single-channel properties | Amiodarone | Dronedarone | Propranolol | Pindolol | |||||||
| 3 µM | 10 µM | 0.3 µM | 1 µM | 3 µM | 100 µM | 300 µM | 1,000 µM | 100 µM | 300 µM | 1,000 µM | |
| 2.5 ± 0.7 | 6.5 ± 0.3 | 2.1 ± 0.1 | 4.2 ± 1.2 | 1.6 ± 0.4 | 4.4 ± 0.3 | 9 | 3 ± 1 | 4.0 ± 1.2 | 5 | ||
| 3.1 ± 0.5 | 3.6 ± 1.2 | 1.7 ± 0.03 | 2.2 ± 0.7 | 1.8 ± 0.6 | 6.5 ± 0.2 | 11 | 2.2 ± 0.4 | 3.4 ± 1.1 | 4 | ||
| τ13/τ13cntrl | 1.6 ± 0.2 | 3.5 ± 0.2 | 1.5 ± 0.1 | 2.2 ± 0.2 | 4.6 ± 0.8 | 1.1 ± 0.1 | 1.2 ± 0.03 | 1.8 ± 0.2 | 1.0 ± 0.1 | 1.1 ± 0.1 | 1.4 ± 0.3 |
| τ15/τ15cntrl | 1.5 ± 0.3 | 2.3 ± 0.04 | 1.2 ± 0.1 | 1.6 ± 0.3 | 3.0 ± 0.8 | 1.0 ± 0.05 | 1.1 ± 0.1 | 1.4 ± 0.02 | 1.1 ± 0.1 | 1.2 ± 0.2 | 1.3 ± 0.1 |
Values represent relative changes in gA channels’ single-channel appearance frequencies (f) and lifetimes (τ), where f or τ in the presence of antiarrhythmics is normalized to that in the absence of antiarrhythmic in the same experiment.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.